Grace Halsey

"Twincretin" tirzepatide-treated participants in SURMOUNT-5 lost a mean 50 lbs vs an average loss of 33 lbs for those treated with semaglutide.

A geriatric psychiatrist talks about the importance of asking caregivers about behavior in order to understand and treat agitation in Alzheimer dementia.

Aquestive Therapeutics announced positive feedback from the FDA this week that keeps NDA planning for the novel epinephrine product on solid ground.

Holiday health care gift-giving season is here and we've done some window shopping for our primary care readers. Take a breath and scroll through our top 10 suggestions for 2024.

COPD expert MeiLan K Han, MD, MS, says that in the absence of a definitive single tool to assess for COPD, probing patients for risk factors and symptoms is essential.

At least 1 accurate UTI symptom was found on most of the 331 websites reviewed, but nearly all (80%) included at least 1 inaccurate or misleading one.

Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.

Professor MeiLan Han, MD, MS, details inclusion of the 2 new medications and how the additions reflect a focus on disease heterogeneity and precision medicine in in COPD.

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Analysis of surveillance data revealed a decline in use of antiviral medications for children hospitalized with influenza and prevalent underprescribing in outpatient settings.

Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.

"It's a very rich pipeline because [agitation] is a very common and very debilitating symptom in Alzheimer's disease," Grossberg observed.

Physical activity of any level before and after a diagnosis of dementia was associated with at least a 20% lower risk for all-cause mortality across dementia subtypes.

The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.

Among current smokers, 71% had never spoken a clinician about screening and among those who had quit, 75% had never had a conversation.

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

Antipsychotic medications are still used to treat potentially harmful acute agitation, George Grossberg, MD, explains, even though the adverse effects are well known.

The EMA recommendation excludes from treatment adults who are homozygous for the ApoE ε4 gene, a decision that the US Alzheimer's Association does not support, said the president/CEO.

About 40% of people who have T1D are not aware of it until they experience an extreme health event; screening in primary care can help reduce the risk, support families.

Nondrug approaches to calming an adult with Alzheimer disease who is agitated should be prioritized over pharmacotherapy, geriatric psychiatrist George Grossberg, MD, counsels.

When a patient with Alzheimer dementia becomes agitated, check the physical environment for a trigger before pulling the trigger on a medication, dementia expert George Grossberg, MD, recommends.

A quick review of the scope of diabetes in the US and of the gaps in equitable access to care supports the annual call to action from the International Diabetes Federation.

The geriatric psychiatrist refers in this interview to agitation in Alzheimer disease, a significant neuropsychiatric symptom that should not be dismissed.

Michigan Medicine researchers found that at all age levels, women with known/suspected OSA were more likely than men to be diagnosed with dementia.

The 11 words and phrases, among others, are often automatic responses from clinicians in highly emotional settings of severe illness. Find 11 alternatives, here.

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

A decision on ending use of oral phenylephrine as a nasal decongestant in OTC products will be made following public comment on FDA's proposed order.

Dual and triple incretin agonists continue to lead the new therapies in the antiobesity pipeline. Here is an at-a-glance update of their progress toward approval.

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.